Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.66 |
| ▸ | MMP9 | P14780 | 5/20 | 0.66 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414567 | 0.93 | MMP2 (0.67) | MMP2MMP9CA1CA2TLR2 | |
| SCHEMBL13282819 | 0.93 | MMP2 (0.67) | MMP2MMP9CA1CA2TLR2 | |
| SCHEMBL13254807 | 0.82 | MMP2 (0.48) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL13282820 | 0.81 | MMP2 (0.59) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL13254809 | 0.81 | MMP2 (0.59) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL13254806 | 0.76 | MMP2 (0.54) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL7072474 | 0.76 | MMP2 (0.51) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL7072473 | 0.76 | MMP2 (0.51) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL13282810 | 0.76 | MMP2 (0.54) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL13282821 | 0.75 | MMP2 (0.47) | MMP2MMP9TLR2TLR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196112-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066533-A1 | Cell adhesion inhibitors | LEE WEN-CHERNG | 2007-03-22 | — | — | US | disclosed |
| US-20070066533-A1 | Cell adhesion inhibitors | LEE WEN-CHERNG | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066533-A1 | Cell adhesion inhibitors | VCAM1, EPCAM, ICAM1 | MMP2 611/4885MMP9 741/4885CA1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.